Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_assertion type Assertion NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_head.
- NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_assertion description "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_provenance.
- NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_assertion evidence source_evidence_literature NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_provenance.
- NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_assertion SIO_000772 12810660 NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_provenance.
- NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_assertion wasDerivedFrom befree-20140225 NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_provenance.
- NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_assertion wasGeneratedBy ECO_0000203 NP870643.RAMSXOLSAoeG2V50Pq9hUUyXA6Oav0Kdq7pznr4pCoNPk130_provenance.